SEER Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenue: $2.8 million, down from $4.2 million in Q1 2025.
Product Revenue: $2.1 million; Service Revenue: $0.6 million.
Gross Profit: Approximately $1 million, with a gross margin of 35%, down from 49% in Q1 2025.
Operating Expenses: $18.2 million, reduced from $22.8 million in Q1 2025.
Net Loss: $16.8 million, improved from a loss of $19.9 million in Q1 2025.
Free Cash Flow: Approximately negative $15.7 million.
Cash Position: $219.5 million in cash and equivalents.
Share Repurchase: 1.5 million shares repurchased at an average price of $1.78.

2. Strategic Updates and Business Highlights

Innovation and Collaborations: Continued expansion of independent publications validating the Proteograph platform, now totaling 84. New biobank collaboration with Precision Health Research and Thermo Fisher announced.
Leadership Changes: Appointment of Tony Bazarko as Chief Commercial Officer to enhance sales momentum.
Intellectual Property: Successful defense of patents and initiation of a patent infringement lawsuit against Nanomix Biotechnology.
Insight Grant Program: Evolved to include a new biopharma development track to engage pharmaceutical teams directly.

3. Forward Guidance and Outlook

Revenue Guidance for 2026: Reaffirmed at $16 million to $18 million, representing approximately 3% growth at the midpoint over 2025.
Market Confidence: Management expressed confidence in revenue growth driven by ongoing biobank partnerships and the anticipated impact of large-scale studies.

4. Bad News, Challenges, or Points of Concern

Revenue Decline: Significant drop in revenue attributed to a depressed academic funding environment and increased competition from inferior products.
Gross Margin Pressure: Lower absorption of fixed costs contributed to reduced gross margins, with expectations for variability in future quarters.
Market Competition: Emergence of imitators with inferior products posing risks to market share and customer trust.
Service Revenue Decline: Service revenue was notably lower due to the absence of large projects in Q1, highlighting potential volatility in this segment.

5. Notable Q&A Insights

Customer Confidence: Management remains optimistic about meeting revenue guidance, citing ongoing discussions with biobanks and biopharma.
Competitor Landscape: Omid Farokhzad emphasized the importance of protecting intellectual property against imitators, asserting that Seer's established reputation and scientific validation will maintain customer trust.
Instrument Utilization Trends: Utilization of installed instruments is project-driven, with expectations for increased reorder rates as customers approach the one-year mark post-installation.
Gross Margin Recovery: Management anticipates that gross margins will improve as revenue increases, returning to the low 50s range as business scales.

This summary encapsulates the key financial metrics, strategic initiatives, forward outlook, challenges, and insights from the Q&A session, providing a comprehensive overview of SEER's performance and strategic direction for Q1 2026.

SEER — Seer, Inc.